Inflammation and oncogenesis: a vicious connection

Current Opinion in Genetics and Development

Volumn 20, Issue 1, 2010, Pages 65-71

  Grivennikov, Sergei I ^a   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

CANCER RISK; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; ULCERATIVE COLITIS;

COLITIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 75849117800     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.11.004     Document Type: Review

References (89)

1. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148. Seminal review that discusses in details tumor immunosurveillance and tumor immune escape.
2. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
3. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907. This paper provides unequivocal evidence for the existence of the equilibrium between tumor and immune system in vivo.
4. Bui J.D., and Schreiber R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol 19 (2007) 203-208
5. Naugler W.E., and Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18 (2008) 19-26
6. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
7. Johansson M., Tan T., de Visser K.E., and Coussens L.M. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem 101 (2007) 918-926
8. de Visser K.E., Korets L.V., and Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 (2005) 411-423. This paper demonstrates previously unexpected tumor-promoting role of B lymphocytes in cancer
9. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., and Evan G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13 (2007) 1211-1218
10. Colotta F., Allavena P., Sica A., Garlanda C., and Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009) 1073-1081
11. Sica A., Allavena P., and Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 267 (2008) 204-215
12. Gabrilovich D.I., and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9 (2009) 162-174
13. Roberts S.J., Ng B.Y., Filler R.B., Lewis J., Glusac E.J., Hayday A.C., Tigelaar R.E., and Girardi M. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A 104 (2007) 6770-6775
14. + T cells educate tumor-associated macrophages.
15. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., and Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206 (2009) 1457-1464
16. Langowski J.L., Kastelein R.A., and Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 28 (2007) 207-212
17. •].
18. •] provide solid evidence that T cell infiltration in sporadic colon cancer tumors can be used for the prediction of the outcome of disease and has anti-tumorigenic effect.
19. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., and Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (2005) e284
20. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation and cancer: the good, the bad and the ugly. Cell 2010, in press. This review describes in details types for tumor-promoting inflammation, discusses the role of inflammation at different stages of tumorigenesis, and outlines common specific mechanisms for tumorigenesis driven by inflammation.
21. Greten F.R., and Karin M. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
22. Grivennikov SI, Karin M: Dangerous liasons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2009, doi:10.1016/j.cytogfr.2009.11.005.
23. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7 (2007) 41-51
24. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
25. Ancrile B., Lim K.H., and Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21 (2007) 1714-1719
26. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444. Recent review, which summarizes our current knowledge about cancer related inflammation represented by anti-tumor immunity and cancer-promoting inflammation.
27. DeNardo D.G., Johansson M., and Coussens L.M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27 (2008) 11-18
28. Medzhitov R. Origin and physiological roles of inflammation. Nature 454 (2008) 428-435. Recent review that describes the causes, types, and outcomes of inflammatory reactions.
29. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., Brancati F.L., Wick E., McAllister F., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 (2009) 1016-1022. This paper describes a role of specific strain of commensal bacteria, which can trigger intestinal injury, colitis, and promote tumor growth in a classical sporadic colon cancer model. It also proposes the role of Th17 T cells and STAT3 in tumor promotion.
30. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., and Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 101 (2009) 554-559
31. Yamasaki K., Hayashi Y., Okamoto S., Osanai M., and Lee G.H. Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci 101 (2010) 65-72
32. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., Subramaniam S., Berger N.A., Croniger C., Lambris J.D., et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 18 (2009) 2975-2988
33. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer R, Osterreicher C, Takahashi H, Karin M: Dietary and genetic obesity promote liver carcinogenesis by enhancing IL-6 and TNF expression. Cell 2010, in press.
34. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., and Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 103 (2006) 10741-10746
35. Waldner M.J., and Neurath M.F. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31 (2009) 249-256
36. Kraus S., and Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 9 (2009) 405-410
37. Gao Y., Kristinsson S.Y., Goldin L.R., Bjorkholm M., Caporaso N.E., and Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 136 (2009) 91-98
38. Sparmann A., and Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 (2004) 447-458
39. Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., and Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11 (2009) 973-979
40. Orjalo A.V., Bhaumik D., Gengler B.K., Scott G.K., and Campisi J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 106 (2009) 17031-17036
41. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., and Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15 (2008) 3-12
42. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007) 1050-1059
43. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15 (2009) 1170-1178. This paper shows that chemotherapeutic intervention leads to the activation of inflammasome and production of IL-1b, which drives anti-tumor immune responses.
44. Karin M. NF-κB and cancer: mechanisms and targets. Mol Carcinog 45 (2006) 355-361
45. Hofseth L.J., Khan M.A., Ambrose M., Nikolayeva O., Xu-Welliver M., Kartalou M., Hussain S.P., Roth R.B., Zhou X., Mechanic L.E., et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 112 (2003) 1887-1894
46. Meira L.B., Bugni J.M., Green S.L., Lee C.W., Pang B., Borenshtein D., Rickman B.H., Rogers A.B., Moroski-Erkul C.A., McFaline J.L., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118 (2008) 2516-2525. This paper establishes the role of chronic inflammation in tumor initiation. In a model of chronic chemically induced colitis authors found that chronic inflammation directly induces DNA damage and mutations and causes colitis-associated cancer without administration of environmental mutagen.
47. Sakaguchi T., Brand S., and Reinecker H.C. Mucosal barrier and immune mediators. Curr Opin Gastroenterol 17 (2001) 573-577
48. Takai A., Toyoshima T., Uemura M., Kitawaki Y., Marusawa H., Hiai H., Yamada S., Okazaki I.M., Honjo T., Chiba T., et al. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene 28 (2009) 469-478
49. Matsumoto Y., Marusawa H., Kinoshita K., Endo Y., Kou T., Morisawa T., Azuma T., Okazaki I.M., Honjo T., and Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13 (2007) 470-476
50. Niu G., Wright K.L., Ma Y., Wright G.M., Huang M., Irby R., Briggs J., Karras J., Cress W.D., Pardoll D., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25 (2005) 7432-7440
51. Tergaonkar V., Pando M., Vafa O., Wahl G., and Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1 (2002) 493-503
52. •].
53. •].
54. •].
55. •] cover important advances in how inflammation can stimulate epigenetic silencing of genes relevant to tumorigenesis and enhance tumor initiation and tumor promotion.
56. Murdoch C., Muthana M., Coffelt S.B., and Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8 (2008) 618-631
57. Zumsteg A., and Christofori G. Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 21 (2009) 60-70
58. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
59. Karin M. The IkappaB kinase-a bridge between inflammation and cancer. Cell Res 18 (2008) 334-342
60. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., and Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118 (2008) 3367-3377
61. Niu G., Briggs J., Deng J., Ma Y., Lee H., Kortylewski M., Kujawski M., Kay H., Cress W.D., Jove R., et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6 (2008) 1099-1105
62. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
63. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
64. •].
65. •] establish the role of transcription factor STAT3 expressed by intestinal epithelial cells and STAT3-activating cytokines, such as IL-6 and IL-11 in the regulation of survival and proliferation of epithelial and malignant cells and development of colitis-associated cancer.
66. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
67. Xiao H., Gulen M.F., Qin J., Yao J., Bulek K., Kish D., Altuntas C.Z., Wald D., Ma C., Zhou H., et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26 (2007) 461-475
68. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., and Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 (2009) 283-293. This intriguing paper provides an explanation and a mechanism of how constitutive STAT3 activation in tumors causes prolonged NF-κB activation.
69. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., Matthews V.B., Armes J., Bhathal P.S., Hughes N.R., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118 (2008) 1727-1738. This paper shows the role of IL-11 as well as of STAT1 and STAT3 in gastric cancer that is caused by deregulated gp130-signaling.
70. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14 (2008) 408-419
71. Haura E.B., Turkson J., and Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2 (2005) 315-324
72. Ghoreschi K., Laurence A., and O'Shea J.J. Janus kinases in immune cell signaling. Immunol Rev 228 (2009) 273-287
73. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., and Stark G.R. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65 (2005) 939-947
74. Pickert G., Neufert C., Leppkes M., Zheng Y., Wittkopf N., Warntjen M., Lehr H.A., Hirth S., Weigmann B., Wirtz S., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206 (2009) 1465-1472
75. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9 (2009) 556-567
76. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., and Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118 (2008) 560-570. This paper provides first unequivocal evidence that TNF-α is not only important for IBD development but is also crucial for colitis-associated cancer pathogenesis. Genetic ablation of TNFR1 or pharmacological neutralization of TNF-α significantly decreases tumor numbers and tumor size.
77. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21 (2004) 491-501. This paper first implicates IL-6 trans-signaling into development of colitis-associated cancer and demonstrates that anti-tumorigenic action of TGFβ may be partly explained by its ability to negatively regulate IL-6 signaling.
78. Wu Y., and Zhou B.P. Inflammation: a driving force speeds cancer metastasis. Cell Cycle (2009) 8
79. Yang J., and Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14 (2008) 818-829
80. Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., and Zhou B.P. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15 (2009) 416-428. This study demonstrates how inflammatory NF-κB dependent signaling results in stabilization of Snail. Since Snail is a key regulator of metastasis, this work shows a distinct molecular mechanism how inflammation (particularly NF-κB) can contribute to metastasis.
81. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., and Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 100 (2003) 2645-2650
82. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., Oberyszyn T.M., and Hall B.M. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28 (2009) 2940-2947
83. Kortylewski M., Jove R., and Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24 (2005) 315-327
84. Kitamura T., Kometani K., Hashida H., Matsunaga A., Miyoshi H., Hosogi H., Aoki M., Oshima M., Hattori M., Takabayashi A., et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 39 (2007) 467-475
85. Luo J.L., Tan W., Ricono J.M., Korchynskyi O., Zhang M., Gonias S.L., Cheresh D.A., and Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446 (2007) 690-694. This study finds a crucial role of IKKα, an enzyme from alternative NF-κB pathway, in prostate cancer metastasis owing to its ability to inhibit the expression of maspin. Since maspin inhibits the activity of various tissue proteases, its repression aids metastasis development.
86. Grivennikov S.I., Kuprash D.V., Liu Z.G., and Nedospasov S.A. Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol 252 (2006) 129-161
87. Nguyen D.X., Bos P.D., and Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9 (2009) 274-284
88. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
89. Luo J.L., Maeda S., Hsu L.C., Yagita H., and Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297-305